Hydroxytest — hydroxytestosterone

Hydroxytestosterone is an anabolic steroid that, as its name would indicate, is a close structural relative of testosterone. More specifically, it is testosterone with an added 4-hydroxl group, an alteration that drastically alters the activity of this steroid. In action it is only moderately anabolic and androgenic, with both traits significantly reduced in potency compared to testosterone. When looking at its activity profile, hydroxytestosterone is classified as an anabolic steroid, with a much lower level of relative androgenicity compared to the primary male androgen. This steroid is additionally non-estrogenic (antiestrogenic actually), and as such tends to promote lean mass and strength gains, whereas testosterone is primarily thought of as a bulking agent. Ultimately, this steroid bears little resemblance to the androgen that it is so closely related to on a molecular level, and is often applied in very different circumstances by athletes.

Brand name Hydroxytest, Hydroxytestosterone
Androgenic 25
Anabolic 65
Standard Testosterone
Chemical Names 4-hydroxy-androsten-3-one-17beta-ol
Estrogenic Activity none
Progestational Activity no data available (low)

Hydroxytest History

Hydroxytestosterone was originally developed by the pharmaceutical manufacturing giant G.D. & Searle. Methods for its synthesis were first patented in 1956. Studies on its pharmacology were published soon after, and have determined that (when given by injection as an acetate) this steroid had approximately 65% of the anabolic potency of testosterone propionate, with only 25% of the androgenicity. This makes hydroxytestosterone a fairly favorable anabolic drug, displaying a much lower tendency to produce androgenic side effects than to increase protein synthesis. In spite of this, however, the drug never did make it to the shelf as a commercial prescription steroid product. It simply lay lost in the research books for decades, the manufacturer and patent holder probably finding little financial incentive to market it next to the many other anabolic agents available.

Hydroxytestosterone emerged from its research obscurity in 2004, when it was sold very briefly in the United States as an OTC nutritional supplement. This had to do simply with the fact that the steroid was naturally occurring, and (not being developed into a medicine) had not been identified by lawmakers at the time the first Anabolic Steroid Control Act went into effect. It was not specifically included, and thus exempt. As with all naturally occurring non-methylated steroid hormones, however, hydroxytestosterone is not intrinsically very orally active, and pharmaceutical delivery (injection) was not viable as a supplement. Hydroxytestosterone will work, but you must get the steroid into your body first. This necessitated the development of commercial ester-modified softgels (similar to Andriol in design), as well as transdermal formulas (similar to Androgel). Some consumers also made their own injections out of raw hydroxytestosterone powder. While the latter option may be preferred in a bioavailability sense, such practices were generally not recommended, as they were not inclined to produce a sterile pharmaceutical-quality medicine.

This steroid was generally a very effective one, and when sold as a supplement, seemed to be well-tolerated by consumers. There were no reports of acute side effects beyond those produced by the normal androgenic properties of the drug. Still, this agent would be very shortlived on the consumer market. By late 2004, Congress had passed an amendment to the original Anabolic Steroid Control Act that would add a number of OTC compounds to the Federal list of controlled drugs, hydroxytestosterone included. The amended law went into effect in early 2005. All supplement products containing this anabolic steroid were subsequently removed from market. Residual stock was generally pulled from commerce at the same time as well. Presently, hydroxytestosterone is again unavailable to athletes. Its future development into a commercial medicine seems highly unlikely.

How is Hydroxytest Supplied

Hydroxytestosterone is not available as a commercial agent. When produced as a supplement it was found in various oral and transdermal doses.

Structural Characteristics of Hydroxytest

Hydroxytestosterone is a modified form oftestosterone. lt differs by the introduction of a hydroxyl group at carbon 4, which inhibits aromatization and reduces relative steroid androgenicity.

Hydroxytest Side Effects (Estrogenic)

Hydroxytestosterone is not aromatized by the body, and is not measurably estrogenic. Estrogenic side effects such as increased water retention, fat gain, and gynecomastia are not likely with use. Note that hydroxytestosterone also has strong aromatase-inhibiting activities. This steroid differs from the suicide aromatase inhibitor formestane (4-hydroxyandrostenedione) only in that it is the active form of the steroid (17-beta hydroxysteroid) instead of the inactive dione (17-ketosteroid), and in the body is a precursor to formestane. Both formestane and hydroxytestosterone directly inhibit the aromatase enzyme, although the former (possessing a 3-keto group) is a more appropriate fit for the enzyme, and is therefore comparably more effective. Regardless of its lower potency, hydroxytestosterone will still effectively lower serum estrogen, reducing the estrogenic side effects caused by the aromatization of other steroid compounds. This agent may, therefore, be looked at as a dual-purpose anabolic/aromatase-inhibiting drug.

Hydroxytest Side Effects (Androgenic)

Although classified as an anabolic steroid, androgenic side effects are still possible with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Note that hydroxytestosterone is not extensively metabolized by the 5-alpha reductase enzyme, so its relative androgenicity is not greatly altered by the concurrent use of finasteride or dutasteride.

Hydroxytest Side Effects (Hepatotoxicity)

Hydroxytestosterone is not a cl 7-alpha alkylated compound, and not known to have hepatotoxic effects. Liver toxicity is unlikely.

Hydroxytest Side Effects (Cardiovascular)

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Hydroxytestosterone should have a stronger negative effect on the hepatic management of cholesterol than testosterone or nandrolone due to its non-aromatizable nature, but a much weaker impact than c-17 alpha alkylated steroids. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Hydroxytest Side Effects (Testosterone Suppression)

All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

Hydroxytest Administration (Men)

Hydroxytestosterone was never produced as a prescription medication. Prescribing guidelines are unavailable. Effective doses for physique- or performance enhancing purposes are in the range of 200-400 mg per week by injection, or 100-300 mg daily if taking an oil-solubilized oral product or transdermal. Maximum aromatase inhibition is likely reached by 250 mg per week when given by injection, or 100-200 mg per day when taking oral softgels. Users often keep the doses limited to this range if estrogen minimization is the main focus. Hydroxytestosterone and formestane may not be quite as potent as the selective third generation non-steroidal aromatase inhibitors Arimidex or Femara, but they do seem to do a much better job here than the "standard issue" estrogen receptor antagonists Nolvadex and Clomid (especially when it comes to shedding water and producing the tight "high androgen" look). As with all effective aromatase inhibitors, its estrogen-lowering action is likely to be accompanied by a negative lowering of HDL (good) cholesterol levels. For this reason hydroxytestosterone should never be used for long periods of time, and regular doctor's checkups are recommended during use.

Hydroxytest Administration (Women)

Hydroxytestosterone was never produced as a prescription medication. Prescribing guidelines are unavailable. Hydroxytestosterone is not recommended for women for physique- or performance-enhancing purposes due to its strong anti-estrogenic nature and tendency to produce virilizing side effects.

Hydroxytest Availability

Hydroxytestosterone is not available as a prescription agent at this time.


Wlliam Llewellyn (2017) - Anabolics

Your experience with Hydroxytest — hydroxytestosterone

There are no comments yet.